These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 9679526)

  • 1. A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression.
    Beveridge RA; Miller JA; Kales AN; Binder RA; Robert NJ; Harvey JH; Windsor K; Gore I; Cantrell J; Thompson KA; Taylor WR; Barnes HM; Schiff SA; Shields JA; Cambareri RJ; Butler TP; Meister RJ; Feigert JM; Norgard MJ; Moraes MA; Helvie WW; Patton GA; Mundy LJ; Henry D; Sheridan MJ
    Cancer Invest; 1998; 16(6):366-73. PubMed ID: 9679526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial comparing the tolerability of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in cancer patients receiving myelosuppressive chemotherapy.
    Beveridge RA; Miller JA; Kales AN; Binder RA; Robert NJ; Heisrath-Evans J; Koczyk-Scripka K; Pashko S; Norgard MJ; Barnes HM; Taylor WR; Thompson KA; Smith LF; Ueno WM; Dobrzynski RF; Warren RD; Katcher D; Byrne PJ; Dunning DM; Winokur SH; Lockey JL; Cambareri RJ; Butler TP; Meister RJ; Fiegert JM
    Support Care Cancer; 1997 Jul; 5(4):289-98. PubMed ID: 9257425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.
    Weycker D; Malin J; Barron R; Edelsberg J; Kartashov A; Oster G
    Am J Clin Oncol; 2012 Jun; 35(3):267-74. PubMed ID: 21378538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative safety of filgrastim versus sargramostim in patients receiving myelosuppressive chemotherapy.
    Milkovich G; Moleski RJ; Reitan JF; Dunning DM; Gibson GA; Paivanas TA; Wyant S; Jacobs RJ
    Pharmacotherapy; 2000 Dec; 20(12):1432-40. PubMed ID: 11130215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulary management of colony-stimulating factors.
    Whalen CR; Watson TL; Baize T; Ball A
    Am J Health Syst Pharm; 2002 Apr; 59(7 Suppl 2):S21-7. PubMed ID: 11944611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
    Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
    J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
    Heaney ML; Toy EL; Vekeman F; Laliberté F; Dority BL; Perlman D; Barghout V; Duh MS
    Cancer; 2009 Oct; 115(20):4839-48. PubMed ID: 19637341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia.
    Stull DM; Bilmes R; Kim H; Fichtl R
    Am J Health Syst Pharm; 2005 Jan; 62(1):83-7. PubMed ID: 15658078
    [No Abstract]   [Full Text] [Related]  

  • 9. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells.
    Weaver CH; Schulman KA; Wilson-Relyea B; Birch R; West W; Buckner CD
    J Clin Oncol; 2000 Jan; 18(1):43-53. PubMed ID: 10623692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats.
    Nohynek GJ; Plard JP; Wells MY; Zerial A; Roquet F
    Cancer Chemother Pharmacol; 1997; 39(3):259-66. PubMed ID: 8996530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical applications of colony-stimulating factors: a historical perspective.
    Sylvester RK
    Am J Health Syst Pharm; 2002 Apr; 59(7 Suppl 2):S6-12. PubMed ID: 11944613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
    Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
    J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of recombinant granulocyte colony-stimulating factor, recombinant human granulocyte-macrophage colony-stimulating factor and placebo for treatment of septic preterm infants.
    Ahmad A; Laborada G; Bussel J; Nesin M
    Pediatr Infect Dis J; 2002 Nov; 21(11):1061-5. PubMed ID: 12442030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
    Weycker D; Barron RL
    Cancer; 2010 Jun; 116(12):3073; author reply 3073-4. PubMed ID: 20564415
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
    Stahel RA; Jost LM; Cerny T; Pichert G; Honegger H; Tobler A; Jacky E; Fey M; Platzer E
    J Clin Oncol; 1994 Sep; 12(9):1931-8. PubMed ID: 7521907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial.
    Maher DW; Lieschke GJ; Green M; Bishop J; Stuart-Harris R; Wolf M; Sheridan WP; Kefford RF; Cebon J; Olver I; McKendrick J; Toner G; Bradstock K; Lieschke M; Cruickshank S; Tomita DK; Hoffman EW; Fox RM; Morstyn G
    Ann Intern Med; 1994 Oct; 121(7):492-501. PubMed ID: 7520676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project.
    Mamounas EP; Anderson S; Wickerham DL; Clark R; Stoller R; Hamm JT; Stewart JA; Bear HD; Glass AG; Bornstein R
    Am J Clin Oncol; 1994 Oct; 17(5):374-81; discussion 382. PubMed ID: 7522393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
    Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
    Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of two different rG-CSF preparations in the treatment of patients with severe congenital neutropenia.
    Carlsson G; Ahlin A; Dahllöf G; Elinder G; Henter JI; Palmblad J
    Br J Haematol; 2004 Jul; 126(1):127-32. PubMed ID: 15198743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.